Intellia Therapeutics (NTLA) Set to Announce Quarterly Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($1.37) per share for the quarter.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The business had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $19.68 million. The company’s revenue for the quarter was down 48.5% on a year-over-year basis. During the same quarter last year, the firm earned ($1.40) earnings per share. On average, analysts expect Intellia Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Intellia Therapeutics Trading Up 0.7 %

Shares of NASDAQ NTLA traded up $0.10 during mid-day trading on Tuesday, reaching $15.24. 1,259,911 shares of the company’s stock were exchanged, compared to its average volume of 1,637,405. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -2.78 and a beta of 1.81. The business has a fifty day simple moving average of $19.70 and a 200 day simple moving average of $22.38. Intellia Therapeutics has a twelve month low of $13.95 and a twelve month high of $34.87.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on NTLA. The Goldman Sachs Group decreased their price objective on Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Citigroup decreased their price target on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Evercore ISI upgraded Intellia Therapeutics to a “strong-buy” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. decreased their price target on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Finally, Chardan Capital decreased their price target on Intellia Therapeutics from $94.00 to $88.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $59.13.

Insider Buying and Selling at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the transaction, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 3.20% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.